Patient data suggest that colony-stimulating factor-1 (CSF1) and its receptor (CSF1R) have critical roles during breast cancer progression. We have previously shown that in human breast tumors expressing both CSF1 and CSF1R, invasion in vivo is dependent both on a paracrine interaction with tumor-associated macrophages and an autocrine regulation of CSF1R in the tumor cells themselves. Although the role of the paracrine interaction between tumor cells and macrophages has been extensively studied, very little is known about the mechanism by which the autocrine CSF1R signaling contributes to tumor progression. We show here that breast cancer patients of the claudin-low subtype have significantly increased expression of CSF1R. Using a panel of breast cancer cell lines, we confirm that CSF1R expression is elevated and regulated by TGFβ specifically in claudin-low cell lines. Abrogation of autocrine CSF1R signaling in MDA-MB-231 xenografts (a claudin-low cell line) leads to increased tumor size by enhanced proliferation, but significantly reduced invasion, dissemination and metastasis. Indeed, we show that proliferation and invasion are oppositely regulated by CSF1R downstream of TGFβ only in claudin-low cell lines. Intravital multiphoton imaging revealed that inhibition of CSF1R in the tumor cells leads to decreased in vivo motility and a more cohesive morphology. We show that, both in vitro and in vivo, CSF1R inhibition results in a reversal of claudin-low marker expression by significant upregulation of luminal keratins and tight-junction proteins such as claudins. Finally, we show that artificial overexpression of claudins in MDA-MB-231 cells is sufficient to tip the cells from an invasive state to a proliferative state. Our results suggest that autocrine CSF1R signaling is essential in maintaining low claudin expression and that it mediates a switch between the proliferative and the invasive state in claudin-low tumor cells downstream of TGFβ.
INTRODUCTION
Breast cancer is one of the most frequent malignant neoplasms occurring in women in developed countries. Recent advances in genomic analysis have greatly advanced our understanding of the heterogeneity of this disease. Five main 'intrinsic' subtypes have been distinguished based on unsupervised clustering of gene expression profiles: the luminal A cancers, which are mostly estrogen receptor (ER) positive and histologically low grade; the luminal B cancers, which are also mostly ER positive but often high grade; the HER2-positive cancers, which show high expression of the ERBB2 gene; the basal-like breast cancers, which are mostly ER negative, progesterone receptor negative and HER2 negative (hence, 'triple negative'); and the newly recognized claudin-low subtype. [1] [2] [3] [4] [5] The claudin-low subtype is constituted mostly of triple-negative tumors that show low expression of luminal differentiation markers, such as tight-and adherens-junction proteins, cadherins and claudins 3, 4 and 7 (hence the name 'claudin-low'). 6, 7 These molecular subtypes show different prognostic outcome as well as treatment sensitivities. However, their use in the clinic has been hindered by technical challenges such as the development of standardized cross-lab assays. 8, 9 Despite this, their unique molecular profiles are most likely due to the involvement of different signaling pathways, and information on such pathways would be useful for assessing prognostic applications and the specification of subtype-specific drugs.
Colony-stimulating factor-1 (CSF1) and its receptor (CSF1R) have been associated with adverse prognostic outcome in tumors of the female reproductive system and other solid tumors. [10] [11] [12] [13] [14] [15] In breast cancer, intravital multiphoton imaging of both transgenic and xenograft mouse models has shown that macrophages are obligate partners of invasion in the primary tumor. [16] [17] [18] CSF1 signaling to the macrophages is essential for this function: genetic ablation of CSF1 in the mammary cancer-susceptible MMTV-PyMT mice delays tumor progression and metastasis, 19 whereas inhibition of CSF1R by blocking antibodies reduces in vivo invasion of tumor cells. 16, 17 Blockade of CSF1 signaling to the macrophages has also been shown to reduce primary tumor growth due to decreased angiogenesis, 20, 21 as well as to improve chemotherapeutic efficacy due to increased antitumor T-cell responses. 22 Interestingly, in humans, CSF1 and CSF1R are co-expressed in the tumor cells of patients, 12, 23 raising the hypothesis that autocrine CSF1R signaling to tumor cells is also important in breast cancer progression. Several studies have now shown that tumor cell lines with artificial overexpression of both CSF1 and CSF1R exhibit increased motility and invasiveness in vitro. [24] [25] [26] We have previously shown that in MDA-MB-231, which spontaneously express both CSF1 and CSF1R without further manipulation, invasion in vivo occurs both through an epidermal growth factor (EGF)/CSF1 paracrine interaction with the macrophages (similar to what was previously reported from mouse mammary tumor studies), and an autocrine CSF1/CSF1R loop in the tumor cells. 27 The above studies argue that CSF1R signaling has great potential as a therapeutic target in breast cancer. Indeed, multiple companies are now investing in developing compounds that would inhibit CSF1R function and several of these compounds are already in clinical trials. However, although extensive data exist on the role of CSF1R in metastatic progression through its role in tumor-associated macrophages, very little is known about the role of autocrine CSF1R signaling in the tumor cells. This knowledge will be instrumental to our in-depth understanding of CSF1R signaling in human breast tumor progression.
RESULTS

Claudin-low breast tumor cells express higher levels of CSF1R regulated by TGFβ
Breast tumors of different intrinsic subtypes are characterized by different gene expression profiles. We were interested in testing whether autocrine CSF1R signaling was correlated with a particular breast cancer subtype. We analyzed a publicly available breast cancer patient cohort (UNC337 database) 7 and found that CSF1R mRNA was expressed at significantly higher levels in claudin-low patients (Figure 1a ). We also analyzed the mRNA expression levels for the ligand CSF1 and found again that claudin-low patients had slightly but significantly higher levels ( Figure 1a ). This suggests that autocrine CSF1R signaling may be more prominent in claudin-low breast cancer cells.
To investigate this further, and because patient data are extracted from whole tissue that contains stroma as well as tumor cells, we tested a panel of breast cancer cell lines representative of the various molecular subtypes (as classified in Prat et al. 7 ). We found that the claudin-low cell lines (MDA-MB-231, Hs578T and BT549) had higher CSF1R expression than the luminal cell lines (MCF7 and T47D; Figures 1b and c; Supplementary Figure 1 ). The basal-like cell line MDA-MB-468 also showed high expression of CSF1R (Figures 1b and c), an observation that was dissimilar to the patient data in Figure 1a . As far as CSF1 is concerned, we found again that the claudin-low cell lines expressed higher mRNA levels (Figures 1b and c), similar to the patient data in Figure 1a . We have previously shown that in MDA-MB-231 cells, the CSF1/CSF1R autocrine loop is enhanced in vivo due to CSF1R upregulation mediated by TGFβ. 27 We sought to investigate whether this was a property of all claudin-low breast cancer cells. We found that CSF1R mRNA was significantly upregulated after TGFβ stimulation in all three claudin-low cell lines tested, but not in the luminal or basal-like lines (although steady-state levels of CSF1R mRNA in MDA-MB-468 cells were similar to claudin-low cells; Figure 1d ). The mRNA levels of CSF1 were unchanged by TGFβ stimulation in all cell lines (Figure 1d ), suggesting that the main regulation of the autocrine loop by TGFβ happens through transcription of the receptor and not the ligand. As a control, we confirmed that all cell lines, with the exception of T47D, were successfully stimulated by TGFβ ( Supplementary Figure 2 ). To verify that CSF1R expression is directly downstream of TGFβ, we examined the CSF1R mRNA levels after knockdown of Smad3, a signaling molecule downstream of the TGFβ receptor. Smad3 knockdown in MDA-MB-231 cells abrogated CSF1R upregulation by TGFβ stimulation, whereas having no effect in MDA-MB-468 cells (Figure 1e ), suggesting again that CSF1R is regulated by TGFβ specifically in claudin-low breast cancer. Claudin-low breast cancer has been shown before to express a molecular profile enriched in TGFβ signaling, 28 and we confirmed here that patients of the claudin-low subtype have significantly higher expression of TGFβ receptors 1 and 2 (TGFBR1 and TGFBR2; Supplementary Figure 3 ), suggesting that the claudin-low tumor cells are presumably more responsive to exogenous TGFβ stimulation. These data taken together imply that autocrine CSF1R signaling is more prominent in claudin-low breast tumor cells and is regulated by TGFβ.
Autocrine CSF1R signaling attenuates proliferation of claudin-low breast cancer cells in vivo and in vitro To investigate further the role of autocrine CSF1R signaling in claudin-low breast tumor cells, we generated stable CSF1Rknockdown MDA-MB-231 cells expressing two different short hairpin RNA (shRNA) sequences, KD1 and KD2 (80 and 70% knockdown respectively; Supplementary Figure 4 ). When injected orthotopically in mice, CSF1R-knockdown cells grew significantly larger tumors than control cells (Figure 2a ). This effect was seen only in vivo, as KD1 and KD2 cells did not show a growth advantage in standard cell culture ( Supplementary Figure 4 ). We found that the enlarged size of KD1 and KD2 tumors was due to increased cell proliferation, as measured by immunohistochemistry for ki67 ( Figure 2b ). We found no difference in apoptosis in these tumors (Supplementary Figure 5 ), suggesting that apoptosis did not contribute to the tumor size difference.
We sought to further investigate this observation by acute inhibition of the cancer cells' CSF1R after the tumor is established. As macrophages also express CSF1R, and because we wanted to specifically address the role of autocrine CSF1R signaling in this study, we used a technique that we have successfully used in the past to differentiate between the autocrine and paracrine CSF1R signaling. 27 As the human breast tumor is growing in a mouse host, an inhibitory antibody specifically recognizing the human CSF1R blocks only the autocrine signaling, whereas an inhibitory antibody specific to the mouse CSF1R blocks only the paracrine signaling with the macrophages (we validated the antibodies in Patsialou et al. 27 ). When parental MDA-MB-231 tumors were treated with the antihuman CSF1R-inhibitory antibody in vivo, proliferation was significantly increased, as evident by immunohistochemistry of tumor sections for two proliferation markers, ki67 and 5-bromodeoxyuridine (BrdU; Figure 2c ). As a control, the anti-mouse CSF1R antibody did not affect proliferation in vivo (ki67 expression difference was not significant, BrdU incorporation was slightly decreased; Figure 2c ). No difference in apoptosis was observed between treatments (Supplementary Figure 5 ). Overall, both by shRNA silencing and antibody inhibition, our results indicate that autocrine CSF1R contributes to attenuation of tumor cell proliferation in vivo.
We next sought to determine whether the CSF1R-dependent proliferation-attenuating phenotype was common to other claudinlow cells. When MDA-MB-231 cells were treated with the inhibitory anti-human CSF1R antibody in vitro, we found no difference in proliferation, as measured with an S-phase cell cycle progression assay by EdU (5-ethynyl-2'-deoxyuridine) incorporation ( Figure 3a ). We have previously found that autocrine CSF1R signaling in MDA-MB-231 cells is prominent only in vivo and is mediated by TGFβ. 27 Thus, to imitate the in vivo environment, we repeated the above experiment in the presence of TGFβ. In breast cancer, TGFβ has been shown to act as a growth inhibitor specifically in ER-negative cancer cells. 29, 30 We show here that indeed in vitro proliferation of MDA-MB-231 cells (an ER-negative cell line) was significantly reduced in the presence of TGFβ (Figure 3a ). Interestingly, inhibition of CSF1R in this setting released the growth inhibitory effect of TGFβ and resulted in increased proliferation ( Figure 3a ). We tested the panel of breast cancer cell lines in the same assay. Overall, the different cell lines had variable proliferation rates with no discernible pattern correlated to their subtype or CSF1R expression levels ( Figure 3b ). We found that proliferation of the claudin-low cell Autocrine CSF1R in claudin-low breast cancer lines Hs578T and BT549 was arrested by TGFβ stimulation similar to MDA-MB-231, and that this arrest was released after inhibition of CSF1R ( Figure 3c ). However, the cells lines of the basal-like and luminal subtypes did not show the same phenotype, with no significant effect in EdU incorporation after TGFβ stimulation and a slight decrease in the presence of the anti-human CSF1R antibody ( Figure 3c ). Others have also reported that inhibition of CSF1R leads to decreased in vitro proliferation of MDA-MB-468 cells via ERK1/2 signaling, but claudin-low cell lines were not tested in that study. 31 We show here that autocrine CSF1R signaling is essential for the growth inhibition phenotype downstream of TGFβ in claudin-low breast tumor cells. Autocrine CSF1R in claudin-low breast cancer Autocrine CSF1R signaling enhances invasion and metastasis of claudin-low breast cancer in vivo and in vitro We next sought to investigate the role of autocrine CSF1R signaling in metastatic progression of breast cancer cells. We analyzed orthotopic tumors generated from the CSF1Rknockdown cells, KD1 and KD2, compared with equal size control tumors for their invasive and metastatic properties. We found that, compared with control, both KD1 and KD2 tumors showed significantly reduced invasion toward EGF (Figure 4a ), reduced numbers of circulating tumor cells in the peripheral blood ( Figure 4b ), as well as reduced lung metastasis ( Figure 4c ). As macrophages are essential for invasion and metastasis, 32 we tested for the numbers of infiltrating macrophages in control, KD1 and KD2 tumors and found no significant difference (Supplementary Figure 6 ). Finally, when we measured experimental metastasis, where tumor cells are artificially introduced in the blood circulation bypassing invasion and intravasation, we found that lung metastasis now appeared increased for the KD1 cells (Figure 4d ), in agreement with these cells having enhanced growth ( Figure 2 ).
To study further the role of autocrine CSF1R signaling in in vivo invasion, we used intravital multiphoton imaging to visualize migration and invasion in primary tumors at single-cell resolution in real-time. We treated mice bearing orthotopic tumors of MDA-MB-231 cells with either a control immunoglobulin G (IgG) or the inhibitory anti-human CSF1R antibody, after which we imaged the tumors by multiphoton microscopy. Tumor cells were visualized by stable GFP (green fluorescent protein) expression, blood vessels by intravenous injection of fluorescent dextrans and collagen fibers by second harmonic generation. On analysis of four-dimensional (4D) time-lapse images from the primary tumors, we found that inhibition of autocrine CSF1R led to a significant decrease in overall tumor cell motility in vivo (Figure 5a ; Supplementary Movies 1-4). Acute inhibition of autocrine CSF1R signaling also led to decreased intravasation, as measured by multiphoton imaging of photoconverted tumor cells near flowing blood vessels (Figure 5b ), as well as by count of circulating tumor cells in the blood (Figure 5c ). Overall, by both shRNA silencing as well as by antibody inhibition, our results indicate that autocrine CSF1R signaling is essential for tumor cell motility, invasion, intravasation and spontaneous lung metastasis in vivo. Finally, we sought to test whether the CSF1R role in enhancing invasion was common to the claudin-low cell lines. We tested invasion in vitro in matrigel-coated chambers in the presence of TGFβ and the anti-human CSF1R inhibitory antibody. Interestingly, TGFβ stimulation alone did not increase basal invasion of MDA-MB-231 cells in this experiment, probably due to low treatment time (cells were exposed to TGFβ within invasion chambers overnight, while previously it had been used as a long pretreatment before invasion assays; 33 Figure 6a ). However, CSF1R inhibition in the presence of TGFβ significantly decreased invasion in MDA-MB-231 cells (Figure 6a ). We tested our panel of breast cancer cells for in vitro invasion in the same assay and found that the luminal T47D and MCF7 cells showed minimal to no invasion in vitro (Figure 6b) . However, when we tested the remaining cell lines, only the claudin-low cells showed a significant decrease in invasion in the presence of TGFβ and the inhibitory anti-CSF1R antibody similar to MDA-MB-231 ( Figure 6c ). In contrast, the basallike MDA-MB-468 cells showed no significant change in invasion with either treatment (Figure 6c ). The above data taken together show that autocrine CSF1R signaling enhances invasion and metastasis in claudin-low breast cancer cells in vitro and in vivo.
Autocrine CSF1R signaling attenuates expression of tight-junction proteins and maintains the 'claudin-low' state By closer observation of our intravital 4D movies, morphological differences between the primary tumors became apparent; control MDA-MB-231 cells were elongated and widely disconnected with each other, whereas CSF1R inhibition resulted to tumor cells that appeared more homogeneous, round and cohesive ( Figure 5 ; Supplementary Movies 1-4 ). Because CSF1R expression is higher in claudin-low patient tumors and cells lines ( Figure 1 ) and because cohesiveness in epithelial cells is associated with expression of junction proteins (such as claudins), we hypothesized that autocrine CSF1R in breast tumor cells may be a regulator of claudins and other luminal proteins. To test this hypothesis, we analyzed the gene expression of MDA-MB-231 cells after inhibition of CSF1R signaling. We tested for standard markers used to characterize claudin-low tumors in the published literature (luminal keratins 8 and 19, as well as claudins 3, 4, 7 and occludin). 7 We also tested for the atypical claudin 11, although very little is known about this protein in breast cancer, because a previous proteomics analysis showed potential interaction of claudin 11 with the activated CSF1R. 34 We found that mRNA expression of luminal keratins 8 and 19 (KRT8 and KRT19) as well as tight-junction proteins claudin 4, 7, 11 and occludin (CLDN4, CLDN7, CLDN11 and OCLN) were significantly upregulated after CSF1R inhibition in vitro (Figure 7a ). We confirmed this result in MDA-MB-231 cells by a second method, namely, CSF1R knockdown by small interfering RNA (siRNA; Supplementary Figure 7A ). We also confirmed that a similar overexpression of keratin 8 and claudins 3, 4 and 7 was evident after CSF1R inhibition in a second claudin-low cell line, Hs578T (Supplementary Figure 7B) . Moreover, we analyzed the gene expression of MDA-MB-231 tumors after CSF1R inhibition in vivo and found again a significant upregulation of luminal keratins and tight-junction proteins (Figure 7b ). We validated the upregulation of several of these markers by western blot analysis in vitro (Figure 7c) , and by immunohistochemistry of tumor tissue sections in vivo (Figure 7d ). Similar to our observation from the intravital imaging ( Figure 5 ; Supplementary Movies 1-4) , the immunohistochemical analysis also revealed that CSF1Rinhibited tumor cells appear in larger nests than the control tumor cells, suggesting that CSF1R inhibition may be associated with increased cohesion (Figure 7d ). Our data indicate that autocrine CSF1R signaling suppresses gene expression of luminal keratins and tight-junction proteins and is essential for maintaining the 'claudin-low' state.
Finally, we sought to determine whether upregulation of these tight-junction proteins was sufficient to recapitulate the phenotype of CSF1R inhibition: increased proliferation and decreased invasion. We generated stable MDA-MB-231 cell lines overexpressing the genes CLDN7, CLDN11 and OCLN ( Supplementary  Figure 8 ) and tested these cells for their proliferation and invasion properties in vitro, in the presence or absence of TGFβ, as well as after CSF1R inhibition. MDA-MB-231 cells overexpressing CLDN7, CLDN11 and OCLN showed both a significant decrease in invasion through matrigel-coated transwells, as well as a significant increase in proliferation, as measured by EdU incorporation (Figure 7e ). TGFβ stimulation or the inhibitory anti-CSF1R antibody alone had no significant effect in either of these processes (with the exception of occludin-overexpressing cells' proliferation; Figure 7e ). Inhibition of CSF1R in the presence of TGFβ similarly was not sufficient to reverse the abrogation of invasion; however, it significantly decreased proliferation in all overexpressing lines (Figure 3e ). Such a proliferation decrease together with lack of invasion capacity was also evident in luminal cells (Figures 3c  and 6b ), suggesting that artificial overexpression of claudins in MDA-MB-231 forces them to resemble more the luminal T47D and MCF7 cells. Our data shows that increased expression of claudins is sufficient to recapitulate the main phenotypes of autocrine CSF1R inhibition into tipping the balance of breast cancer cells from invasion to proliferative growth.
DISCUSSION
In this study, we have assessed the role of autocrine CSF1R signaling in cancer progression of breast tumor cells. We show that TGFβ signaling upregulates expression of CSF1R specifically in claudin-low breast cancer cells, which in turn is essential for maintaining the 'claudin-low' state; when CSF1R is inhibited, expression of luminal keratins and tight-junction proteins is upregulated. The end phenotype of this autocrine CSF1R signaling determines the balance of the claudin-low tumor cells to either proliferate ('grow') or invade ('go'); when autocrine CSF1R signaling is present, junction proteins are suppressed and the balance is tipped over to invasion. In contrast, when autocrine CSF1R is inhibited, expression of junction proteins is released and the balance is tipped over to proliferation. A schematic for the proposed model of how autocrine CSF1R regulates progression in claudin-low breast tumor cells is shown in Figure 8 .
Our in silico analysis of publicly available breast cancer patient microarray data 7 for mRNA levels of CSF1R and its ligand CSF1 showed that both are significantly higher in claudin-low tumors. A previously published analysis of older patient cohorts did not find a correlation for either CSF1 or CSF1R with tumor subtype, however, claudin-low tumors were not separated from basal-like tumors in those cohorts, therefore masking any differences in gene expression. 31 Despite both basal-like and claudin-low tumors being mostly triple negative, claudin-low tumors show lesser expression of proliferation genes than basal-like tumors and are proposed to be slower-cycling tumors. 7 This could be partially explained by the findings presented in this study: autocrine CSF1R signaling attenuates proliferation in the presence of TGFβ specifically in claudin-low tumor cells, but not in basal-like tumor cells. More importantly, although the growth inhibitory effect of TGFβ in ER-negative breast cancer cells has been shown before, no previous report has shown a link for this phenotype to CSF1R signaling. We show here that autocrine CSF1R signaling is downstream of TGFβ, and essential both for the growth inhibitory effect as well as the pro-invasive effect of TGFβ signaling in claudin-low breast tumor cells. Interestingly, these phenotypes were not evident in ER-positive tumor cells. How CSF1R is regulated specifically in claudin-low breast tumor cells but not in ER-positive cells is a study that is underway in our lab. Overall, this is the first study to link CSF1R signaling to the claudin-low breast cancer subtype and the first study to show that CSF1R is a main regulator of a 'go or grow' switch in claudin-low breast cancer cells.
Moreover, we show here that autocrine CSF1R signaling is required for the maintenance of the claudin-low state in breast cancer cells, as inhibition of CSF1R leads to upregulation of claudins and occludin. TGFβ signaling has been previously shown to repress gene expression of claudins, mainly through the action of such transcription factors such as Snail, Slug and Zeb1. [35] [36] [37] This is the first study to show that CSF1R signaling is essential for this function and it is possible that these transcription factors can act Autocrine CSF1R in claudin-low breast cancer downstream of autocrine CSF1R signaling. Interestingly, we found that overexpression of claudins was sufficient to lead to increased proliferation and decreased invasion in the MDA-MB-231 cells in vitro. The role of claudins in cancer progression is currently under intense investigation, with reports showing that they can act both as tumor suppressors and metastasis promoters. 38 Claudins 1, 3 and 4 have been shown to be associated with high grade and poor prognosis in gastric, colon and breast carcinoma, [39] [40] [41] and claudin-1 overexpression leads to enlarged colon tumors in xenograft mice. 41 This agrees with our current study where overexpression of claudins 7, 11 and occludin led to increased cell proliferation. As far as metastasis is concerned, claudin 11 expression leads to decreased invasion in gastric cancer cells 42 and similarly we found here that overexpression of claudin 7, 11 and occludin leads to decreased invasion in MDA-MB-231 cells. It is possible that the opposite effect of claudins in proliferation versus invasion could account for their perceived role as both tumor suppressors and promoters. Of note, our report is the first study to show a role for claudin 11 in invasion and proliferation of breast cancer cells.
Overall, CSF1R has been shown to contribute to metastatic progression of breast cancer mainly through its role in tumorassociated macrophages. 43, 44 The main expectation for inhibition of CSF1R as a therapeutic target is that it will act on the macrophages to potentially revert them back to their normal function of attacking the tumor cells, enhance cytotoxic chemotherapeutic effects and potentially also block their metastasispromoting functions. 45 However, tumor cells in patients also express CSF1R, 23 and so far we have little information on how pharmaceutical inhibition would affect the tumor cells. We show here that inhibition of CSF1R can have very different effects in tumor cells of different subtypes: although proliferation of luminal and basal-like cells was decreased, proliferation of claudin-low tumor cells was significantly increased. This suggests that CSF1R inhibition may have different results depending on the patient molecular subtype and that patients may need to be subdivided by subtype for such inhibitors to be tested efficiently in the clinic.
MATERIALS AND METHODS
Cell lines
MDA-MB-231, Hs578T, BT549, MCF7, T47D and MDA-MB-468 cells (ATCC, Manassas, VA, USA) were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum, antibiotics (Invitrogen, Grand Island, NY, USA) and insulin (Invitrogen) as suggested by ATCC. MDA-MB-231-GFP cells used to generate fluorescent tumors for intravital imaging were described previously. 27 Knockdown and overexpressor MDA-MB-231 stable lines were generated by transduction with lentiviral particles purchased from the Einstein shRNA Core Facility. CSF1R shRNA sequences were RHS4430-101025591 and RHS4430-101031387 (Open Biosystems, Pittsburgh, PA, USA). Stable cell lines were selected with 10 μg/ml puromycin. A control cell line was generated with empty pGIPZ vector. Overexpression constructs were HsCD00434487 for CLDN7, PLOHS_100008613 for CLDN11 and PLOHS_100010097 for OCLN, and vector encoding RFP as a control (Open Biosystems). Stable cell lines were selected with 10 μg/ml blasticidin.
Antibodies and siRNA
Inhibition experiments' antibodies: anti-mouse CSF1R antibody (AFS98) 46 and anti-human CSF1R antibody (MAB3291, R&D Systems, Minneapolis, MN, USA). Western blot antibodies: anti-KRT8/18 (4546, Cell Signaling, Danvers, MA, USA), anti-CLDN7 (34-9100, Invitrogen), anti-CLDN11 (ab53041, Abcam, Cambridge, MA, USA) and anti-OCLN (H00004950-M03A, Novus Biologicals, Littleton, CO, USA). Immunohistochemistry: anticleaved caspace-3 (9661, Cell Signaling), anti-Iba1 (019-19741, Wako Chemicals, Richmond, VA, USA), anti-Ki67 (VP-K451, Vector, Burlingame, CA, USA), anti-BrdU (11170376001, Roche, New York, NY, USA) and anti-KRT8 (ab107115, Abcam). siRNAs: CSF1R gene (M-003109-03-0005, Dharmacon, Pittsburgh, PA, USA) and Smad3 gene (M-020067-00-0005, Dharmacon), both transfected by nucleofection as per the manufacturer's instructions (Lonza, Basel, Switzerland).
In vitro proliferation by EdU incorporation
Cells (200 000) were split into glass-bottom dishes (P35G-1.5-10-C, Mattek, Ashland, MA, USA). Next day, 10 ng/ml TGFβ1 (100-B-001/CF, R&D Systems), control IgG or inhibitory anti-human CSF1R antibody (10 μg/ml) were added for 24 h. Staining for EdU was performed with the Click-iT EdU Alexa Fluo 488 kit as per the manufacturer's instructions (C10350, Invitrogen). Nuclei were counterstained with 4,6-diamidino-2phenylindole. Samples were imaged at × 40 magnification with an Inverted Olympus IX70 microscope (Olympus, Center Valley, PA, USA) (at least 15 random images per dish, three different experiments with duplicate dishes each). Processing and quantification were performed in ImageJ (National Institutes of Health, Bethesda, MD, USA). Results were calculated as percentage of EdU-positive nuclei over total.
Transwell invasion assay
Invasion was evaluated as described previously; 47 10 ng/ml TGFβ1, control IgG or inhibitory anti-human CSF1R antibody (10 μg/ml) were added in both the upper and lower chambers.
Westen blot
MDA-MB-231 cells were treated in vitro with either control IgG or inhibitory anti-human CSF1R antibody (50 μg/ml) in complete media for 48 h, after which they were lyzed and assayed by western blot as previously described. 47 RNA extraction and PCR RNA extraction from cultured cells and from primary tumor cells (495% pure tumor cell population by fluorescence-activated cell sorting), reverse transcription and amplification were performed as previously described. 27, 48 Gene-specific primer sequences are shown in the Supplementary Table. Mouse xenograft model All procedures were conducted in accordance with the National Institutes of Health regulations, and approved by the Einstein animal care committee. A total of 2 × 10 6 MDA-MB-231 cells (parental, expressing GFP, 27 vector control or CSF1R shRNA-knockdown cells) per animal were suspended in sterile phosphate-buffered saline with 20% collagen I (BD Biosciences, San Jose, CA, USA) and injected into the lower left mammary gland of SCID mice (NCI, Frederick, MD, USA). Tumor growth for the knockdown cell lines was measured at 9 weeks post injection according to the formula V = W 2 × L/2 (W: width, L: length). All other experiments were performed on tumors that were 1-1.2 cm in diameter. For treatments with the blocking antibodies, mice were injected intraperitoneally twice at 48 Figure 8 . Model for the role of autocrine CSF1R signaling in claudinlow breast tumor cells. In claudin-low breast tumor cells, TGFβ signaling leads to upregulation of CSF1R. Autocrine CSF1R is a main signal for maintaining the breast tumor cells in a 'claudin-low' state, by repressing expression of claudins and luminal keratins. As an end phenotype, autocrine CSF1R signaling regulates the balance between the 'go or grow' states of the claudin-low breast tumor cells. When CSF1R signaling is inhibited, mRNA expression of claudins and luminal keratins is increased and the cells change from a 'low growth-increased invasion' phenotype to an 'increased growth-low invasion' phenotype. and 24 h before experiments. For histology and immunostaining experiments, primary tumors were excised, fixed in formalin and paraffin embedded. Sections from the middle of the primary tumors were stained with hematoxylin and eosin for general histology, or immunostained with specific antibodies, as described previously. 47, 48 Necrotic tumor areas were excluded from the analysis (no significant difference in overall necrosis was seen between cell lines).
In vivo invasion assay
Cell collection of invasive cells from primary tumors was performed as previously described. 27, 48, 49 Intravasation assay
The number of circulating tumor cells in the peripheral blood of tumorbearing mice was calculated as previously described. 48, 50 Lung metastasis assays Spontaneous lung metastases and experimental lung metastasis in MDA-MB-231 xenografts were performed as previously described. 47 
Intravital imaging
Intravital imaging was performed as described in Patsialou. 18 Briefly, orthotopic tumors of MDA-MB-231-GFP cells at 0.8-1 cm diameter were exposed by skin flap surgery on anesthetized mice, and imaging was performed using an Olympus FV1000-MPE multiphoton system with 880 nm excitation. We imaged random fields of 512 × 512 μm at 512 × 512 pixels for a depth of 100 μm (21 slices at 5 μm steps) beginning at the edge of the tumor for a total of 30 min (2-min intervals). Images were reconstructed in 4D using ImageJ. For the in vivo intravasation assay, the mammary imaging window implantation and photoconversion were performed as described previously. 51, 52 Photoconversion sites were chosen in areas containing at least one flowing blood vessel. Imaging of the photoconverted areas at 0 and 24 h was performed using a custom-built multiphoton system. 53 Imaging and quantification on ImageJ was performed as described previously. 51 
Analysis of breast cancer cohort microarray data
For the UNC337 cohort, gene expression and clinical data published in Prat et al. 7 were downloaded from the UNC Microarray Database (https:// genome.unc.edu). Gene expression data for CSF1 and CSF1R were extracted and grouped by molecular subtype as annotated in the accompanying clinical patient datasheet. Plots and statistical analysis were generated in GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA).
